303-16-2Relevant articles and documents
NEW CRBN MODULATORS
-
Paragraph 0156-0158, (2020/01/24)
Disclosed are degraders, pharmaceutical compositions containing them, and methods of making and using the degraders to treat diseases and disorders characterized by dysregulated or dysfunctional protein activity that can be targeted by cereblon.
TUNABLE ENDOGENOUS PROTEIN DEGRADATION WITH HETEROBIFUNCTIONAL COMPOUNDS
-
Page/Page column 278-279; 280, (2018/09/08)
The present invention provides a means to modulate gene expression in vivo in a manner that avoids problems associated with CRISPR endogenous protein knock-out or knock-in strategies and strategies that provide for correction, or alteration, of single nucleotides. The invention includes inserting into the genome a nucleotide encoding a heterobifunctional compound targeting protein (dTAG) in-frame with the nucleotide sequence of a gene encoding an endogenously expressed protein of interest which, upon expression, produces an endogenous protein-dTAG hybrid protein. This allows for targeted protein degradation of the dTAG and the fused endogenous protein using a heterobifunctional compound.
Studies of unusual amino acids and their peptides. V. The synthesis and the absolute configuration of β (2 thiazolyl) β alanine present in bottromycin
Seto,Torii,Bori,et al.
, p. 151 - 155 (2007/10/04)
-